Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Nuclear medicine studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malignancies. Benign and malignant lesions can be identified on planar, SPECT, and PET scans. This review will outline the mol...

Full description

Saved in:
Bibliographic Details
Published in:Radiology. Imaging cancer 2020-03, Vol.2 (2), p.e190037-e190037
Main Authors: Rahman, W Tania, Neal, Colleen H, Nees, Alexis Virginia, Brown, Richard K J
Format: Article
Language:English
Subjects:
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nuclear medicine studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malignancies. Benign and malignant lesions can be identified on planar, SPECT, and PET scans. This review will outline the molecular and radiographic imaging appearance of benign and malignant breast lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies using fluorine 18 ( F) fluorodeoxyglucose, gallium 68 ( Ga) tetraazacyclododecane tetraacetic acid octreotate (or DOTATATE), Ga prostate-specific membrane antigen, and F-fluciclovine radiotracers. Recognizing these lesions at molecular and anatomic imaging is important to ensure accurate diagnosis and appropriate management. Breast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/CT © RSNA, 2020.
ISSN:2638-616X
2638-616X
DOI:10.1148/rycan.2020190037